AR048891A2 - Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv - Google Patents
Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hivInfo
- Publication number
- AR048891A2 AR048891A2 ARP050101848A ARP050101848A AR048891A2 AR 048891 A2 AR048891 A2 AR 048891A2 AR P050101848 A ARP050101848 A AR P050101848A AR P050101848 A ARP050101848 A AR P050101848A AR 048891 A2 AR048891 A2 AR 048891A2
- Authority
- AR
- Argentina
- Prior art keywords
- solution
- weight
- pharmaceutically acceptable
- pharmaceutical composition
- amount
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004030 hiv protease inhibitor Substances 0.000 title 1
- 150000004668 long chain fatty acids Chemical class 0.000 abstract 2
- AMPWQTJNJASABL-UHFFFAOYSA-N 1,6-diphenylhexan-1-amine Chemical compound C=1C=CC=CC=1C(N)CCCCCC1=CC=CC=C1 AMPWQTJNJASABL-UHFFFAOYSA-N 0.000 abstract 1
- -1 2,6-dimethylphenoxyacetyl Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Una composicion farmacéutica que es una solucion que comprende: (a) (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil)amino-3-hidroxi-5-(2S-(1-tetrahidropirimid-2-onil)-3-metilbutanoil)amino-1,6-difenilhexano en la cantidad de, desde aproximadamente 1% a aproximadamente 50% en peso de la solucion total; (b) un solvente orgánico farmacéuticamente aceptable que comprende (i) un ácido graso de cadena larga farmacéuticamente aceptable de la cantidad de, desde aproximadamente 20% a aproximadamente 99%, en peso de la solucion total o (ii) una mezcla de (1) un ácido graso de cadena larga farmacéuticamente aceptable de desde 20% a aproximadamente99%, en peso de la solucion total y (2) un alcohol farmacéuticamente aceptable en la cantidad de, desde aproximadamente 0% a aproximadamente 15%, en peso de la solucion total; y (c) un surfactante farmacéuticamente aceptable en la cantidad de, desde aproximadamente 0% a aproximadamente 40%, en peso de la solucion total.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75439096A | 1996-11-21 | 1996-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048891A2 true AR048891A2 (es) | 2006-06-07 |
Family
ID=25034589
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970105444A AR010634A1 (es) | 1996-11-21 | 1997-11-20 | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv |
ARP050101848A AR048891A2 (es) | 1996-11-21 | 2005-05-06 | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970105444A AR010634A1 (es) | 1996-11-21 | 1997-11-20 | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP0942721B1 (es) |
JP (2) | JP3592337B2 (es) |
KR (2) | KR100478075B1 (es) |
CN (3) | CN1989963B (es) |
AR (2) | AR010634A1 (es) |
AT (1) | ATE231393T1 (es) |
AU (1) | AU717546B2 (es) |
BG (1) | BG64411B1 (es) |
BR (1) | BR9714310A (es) |
CA (2) | CA2505430A1 (es) |
CZ (1) | CZ299728B6 (es) |
DE (1) | DE69718668T2 (es) |
DK (1) | DK0942721T3 (es) |
ES (1) | ES2191862T3 (es) |
HK (1) | HK1053787A1 (es) |
HU (1) | HU224319B1 (es) |
IL (1) | IL129300A (es) |
NO (1) | NO326927B1 (es) |
NZ (1) | NZ335002A (es) |
PL (1) | PL190185B1 (es) |
PT (1) | PT942721E (es) |
SK (1) | SK285022B6 (es) |
TR (1) | TR199901129T2 (es) |
TW (1) | TW475895B (es) |
WO (1) | WO1998022106A1 (es) |
ZA (1) | ZA9710071B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
SI0999826T1 (en) * | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
AU728695B2 (en) * | 1997-07-29 | 2001-01-18 | Boehringer Ingelheim International Gmbh | Self-emulsifying formulation for lipophilic compounds |
CA2294033C (en) * | 1997-07-29 | 2007-01-09 | Pharmacia & Upjohn Company | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
CO5090830A1 (es) * | 1998-07-20 | 2001-10-30 | Abbott Lab | Poliformo de un agente farmaceutico |
EP1712231A3 (en) * | 1998-11-04 | 2007-11-21 | Pharmacia & Upjohn Company LLC | Method for improving the pharmacokinetics of tipranavir |
EP1126847A1 (en) * | 1998-11-04 | 2001-08-29 | PHARMACIA & UPJOHN COMPANY | Method for improving the pharmacokinetics of tipranavir |
US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
US7141593B1 (en) | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
EP1733725B2 (en) * | 1999-06-04 | 2012-08-08 | Abbott Laboratories | Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water |
WO2001034119A2 (en) | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
KR100738276B1 (ko) * | 1999-12-09 | 2007-07-12 | 알자 코포레이션 | 항바이러스성 약제 |
SI1248600T1 (sl) * | 2000-01-19 | 2008-08-31 | Abbott Lab | Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV |
US6448245B1 (en) | 2000-05-04 | 2002-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
US6911214B2 (en) | 2000-09-05 | 2005-06-28 | Abbott Laboratories | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
EP1395249A1 (en) * | 2001-05-25 | 2004-03-10 | Abbott Laboratories | Soft elastic capsules comprising ritonavir and/or lopinavir |
BR0202252A (pt) * | 2002-06-12 | 2004-06-29 | Cristalia Prod Quimicos Farm | Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease |
BR0302424A (pt) * | 2003-07-23 | 2005-03-29 | Cristalia Prod Quimicos Farm | Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
BRPI0512970A (pt) | 2004-07-06 | 2008-04-22 | Abbott Lab | prodrogas de inibidores da hiv protease |
MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
US9096556B2 (en) | 2011-05-27 | 2015-08-04 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
MX2014013326A (es) | 2012-05-03 | 2015-08-10 | Cipla Ltd | Composición antirretroviral. |
US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE170169T1 (de) * | 1990-11-19 | 1998-09-15 | Monsanto Co | Retrovirale protease inhibitoren |
RU2131420C1 (ru) * | 1991-10-11 | 1999-06-10 | Дзе Дюпон Мерк Фармасьютикал Компани | Циклические мочевины, способ ингибирования роста ретровирусов и фармацевтическая композиция |
CA2081970C (en) * | 1991-11-08 | 1997-07-08 | Joseph P. Vacca | Hiv protease inhibitors useful for the treatment of aids |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
EP0641333B1 (en) * | 1992-05-20 | 1996-08-14 | G.D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
DE69334250D1 (de) * | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
-
1997
- 1997-11-07 ZA ZA9710071A patent/ZA9710071B/xx unknown
- 1997-11-12 CN CN200510128757XA patent/CN1989963B/zh not_active Expired - Lifetime
- 1997-11-12 AU AU52573/98A patent/AU717546B2/en not_active Expired
- 1997-11-12 SK SK655-99A patent/SK285022B6/sk not_active IP Right Cessation
- 1997-11-12 DE DE69718668T patent/DE69718668T2/de not_active Expired - Lifetime
- 1997-11-12 IL IL12930097A patent/IL129300A/xx not_active IP Right Cessation
- 1997-11-12 BR BR9714310-3A patent/BR9714310A/pt active IP Right Grant
- 1997-11-12 ES ES97947510T patent/ES2191862T3/es not_active Expired - Lifetime
- 1997-11-12 KR KR10-1999-7004469A patent/KR100478075B1/ko not_active IP Right Cessation
- 1997-11-12 TR TR1999/01129T patent/TR199901129T2/xx unknown
- 1997-11-12 PL PL97336980A patent/PL190185B1/pl unknown
- 1997-11-12 AT AT97947510T patent/ATE231393T1/de active
- 1997-11-12 CA CA002505430A patent/CA2505430A1/en not_active Abandoned
- 1997-11-12 DK DK97947510T patent/DK0942721T3/da active
- 1997-11-12 CA CA002271196A patent/CA2271196C/en not_active Expired - Lifetime
- 1997-11-12 CN CNA2006101019049A patent/CN101103984A/zh active Pending
- 1997-11-12 JP JP52375198A patent/JP3592337B2/ja not_active Expired - Lifetime
- 1997-11-12 NZ NZ335002A patent/NZ335002A/en not_active IP Right Cessation
- 1997-11-12 CZ CZ0160299A patent/CZ299728B6/cs not_active IP Right Cessation
- 1997-11-12 KR KR10-2003-7006036A patent/KR100516567B1/ko not_active IP Right Cessation
- 1997-11-12 EP EP97947510A patent/EP0942721B1/en not_active Expired - Lifetime
- 1997-11-12 HU HU0002932A patent/HU224319B1/hu active IP Right Grant
- 1997-11-12 PT PT97947510T patent/PT942721E/pt unknown
- 1997-11-12 CN CNB971997802A patent/CN1250219C/zh not_active Expired - Lifetime
- 1997-11-12 EP EP02011533A patent/EP1283041A1/en not_active Withdrawn
- 1997-11-12 WO PCT/US1997/020794 patent/WO1998022106A1/en not_active Application Discontinuation
- 1997-11-17 TW TW086117136A patent/TW475895B/zh active
- 1997-11-20 AR ARP970105444A patent/AR010634A1/es active IP Right Grant
-
1999
- 1999-05-20 NO NO19992427A patent/NO326927B1/no not_active IP Right Cessation
- 1999-05-21 BG BG103425A patent/BG64411B1/bg unknown
-
2000
- 2000-03-17 HK HK03104467.3A patent/HK1053787A1/zh unknown
-
2004
- 2004-06-01 JP JP2004163024A patent/JP4523799B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-06 AR ARP050101848A patent/AR048891A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048891A2 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
ES2157307T3 (es) | Composicion topica que contiene un antagonista de sustancia p. | |
YU39800A (sh) | Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze | |
AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
DE69434626D1 (de) | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten | |
AR062931A2 (es) | Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
TR200002159T2 (tr) | NSAI ilaçların verilmesi için topikal bileşimler. | |
EA199800563A1 (ru) | Антагонисты гормона, высвобождающего гонадотропин | |
AR013506A1 (es) | Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida | |
ATE307569T1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
CO5070655A1 (es) | El compuesto (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amino-3-hidroxi-5-[2s-(1-tetrahidro- pirimid-2-onil)-3-metilbutanoil]amino-1,6-difenilhexano, proceso para su preparacion y formulaciones farmaceuticas que lo contienen | |
PE20021017A1 (es) | Composicion parenteral reconstituible | |
AR039688A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
AR064309A2 (es) | Composicion farmaceutica de ritonavir | |
CO5280073A1 (es) | Composiciones | |
DE69328192D1 (de) | Injizierbare Arzneizubereitungen enthaltend Taxanderivate | |
DK0722313T3 (da) | Viskoelastiske sammensætninger af fluorerede organiske forbindelser | |
BR0007584A (pt) | Polimorfos de telmissartano, processos para preparação dos mesmos e seu uso na preparação de uma composição farmacêutica | |
CO5070569A1 (es) | Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen | |
ES2160680T3 (es) | Utilizacion de un antagonista de sustancia p en una composicion farmaceutica. | |
NL194390B (nl) | Farmaceutische samenstelling die analgetische activiteit bezit met (s)- 2-(6-methoxy-2-naftyl)propionzuur en arginine. | |
AR031358A1 (es) | Combinacion de inhibidores de calpaina y secuestrantes de especies de oxigeno reactivo | |
ES2161247T3 (es) | Preparacion vaginal que contiene un peptido fisiologicamente activo. | |
PT92649A (pt) | Processo para a preparacao do 4-fluoro-2-< { (4-metoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem | |
CR7515A (es) | Composicion veterinaria inyectable para animales pequenos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |